These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15061429)

  • 1. Drug-related dyslipidemia after renal transplantation.
    Mathis AS; Davé N; Knipp GT; Friedman GS
    Am J Health Syst Pharm; 2004 Mar; 61(6):565-85; quiz 586-7. PubMed ID: 15061429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.
    Jardine A; Holdaas H
    J Clin Pharm Ther; 1999 Dec; 24(6):397-408. PubMed ID: 10651972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
    Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
    Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
    Chuang P; Langone AJ
    Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hyperlipidaemia associated with heart transplantation.
    Wenke K
    Drugs; 2004; 64(10):1053-68. PubMed ID: 15139786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
    López V; Gutiérrez C; Gutiérrez E; Sola E; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2008 Nov; 40(9):2925-6. PubMed ID: 19010149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
    Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Utility of pravastin in cardiac transplant dyslipidemia].
    Martínez-Dolz L; Almenar Bonet L; Arnau Vives MA; Rueda Soriano J; Osa Sáez A; Dicenta Gisbert F; Palencia Pérez M
    Rev Clin Esp; 2002 Sep; 202(9):489-91. PubMed ID: 12236939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
    Launay-Vacher V; Izzedine H; Deray G
    Int J Cardiol; 2005 May; 101(1):9-17. PubMed ID: 15860377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
    Spinelli GA; Felipe CR; Park SI; Mandia-Sampaio EL; Tedesco-Silva H; Medina-Pestana JO
    Transplant Proc; 2011 Dec; 43(10):3730-7. PubMed ID: 22172836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients.
    Rodríguez-Ferrero ML; Anaya F
    Transplant Proc; 2008 Dec; 40(10):3492-5. PubMed ID: 19100421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for minimizing hyperlipidemia after cardiac transplantation.
    Kirklin JK; Benza RL; Rayburn BK; McGiffin DC
    Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation.
    Lal SM; Gupta N; Georgiev O; Ross G
    Int J Artif Organs; 1997 Jan; 20(1):18-21. PubMed ID: 9062827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia and its management after renal transplantation.
    Andany MA; Kasiske BL
    J Nephrol; 2001; 14 Suppl 4():S81-8. PubMed ID: 11798152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.